Caspase-6-cleaved tau is relevant in Alzheimer's disease but not in 4-repeat tauopathies: Diagnostic and therapeutic implications.

(1) Caspase-6 activation and cleavage of tau is more prominent in AD and, to a lesser extent, PiD. Caspase-6 modulation could be a promising therapeutic for AD, and possibly PiD, but not 4-repeat tauopathies. (2) In AD, there is a substantial number of neurons with tr-tau inclusions that lack p-tau, which suggests that biofluid biomarkers of tr-tau (specifically at N-terminal sites) would allow for better detection of AD and differentiation of AD from 4-repeat tauopathies.